Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists / 药学实践杂志
Journal of Pharmaceutical Practice
; (6): 496-500, 2020.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-829951
Responsible library:
WPRO
ABSTRACT
Type 2 diabetes is a high risk factor for atherosclerotic cardiovascular disease. Studies have found that SGLT-2 inhibitor and GLP-1 receptor agonists have cardiovascular protective effects in patients with type 2 diabetes and cardiovascular disease. Therefore, from the aspects of cardiovascular safety test and its Meta-analysis and net-like Meta-analysis, the research progress of cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists is summarized.
Full text:
Available
Database:
WPRIM (Western Pacific)
Type of study:
Risk factors
Language:
Chinese
Journal:
Journal of Pharmaceutical Practice
Year:
2020
Document type:
Article
